TIMP2 was initially shown to prohibit cell proliferation and migration via inhibiting the function of MMPs (49), and many studies found that TIMP2 could also be predictive of better prognosis in several cancer types, such as breast cancer (50), gastric cancer (51), colorectal cancer (52), and non-small cell lung cancer (49). This evidence concerns the gene TIMP2 and non-small cell lung carcinoma.